CX-4945
Updated: Nov 14, 2009
| Brand Name: | |
| Generic Name: | |
| Code Name: | CX-4945 |
| Company: | Cylene |
| FDA Clinical Phase: | 1 |
Description:
CX-4945 is an oral anti-cancer agent. It inhibits CK2, an enzyme that plays a role in the development of cancerous cells through cellular processes such as cell cycle regulation, cellular signaling, blood vessel formation, inflammation, and cellular proliferation.
Clinical Trials:
For a list of clinical trials studying CX-4945 for the treatment of multiple myeloma, see ClinicalTrials.gov.
Source: Cylene Pharmaceuticals, http://www.cylenepharma.com/cylene/cx_4945 (as of November 14, 2009)
Related Articles:
- Getting To Know: Tiragolumab
- Common Measures Of Heart And Blood Vessel Health May Predict Risk Of Heart-Related Side Effects During Treatment With Kyprolis
- bb2121 Continues To Impress As Potential New Multiple Myeloma Therapy (ASCO 2018)
- Two Darzalex Clinical Trials Halted; Little Impact Expected On Drug’s Use In Multiple Myeloma
- Eyelid-Related Complications Of Velcade Therapy: New Insights And Recommendations
